Adaptive Biotechnologies (ADPT) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Adaptive Biotechnologies is set to release its Q2 2025 earnings on August 5th, with analysts anticipating a loss of ($0.24) per share and revenue of $49.40 million.
• In its previous quarter, the company reported a loss of ($0.20) per share, exceeding estimates, and achieved a revenue increase of 25.2% year-over-year.
• Institutional investors hold a significant stake in the company, with 99.17% of the stock owned by them and various firms actively adjusting their holdings in recent months.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) will likely be announcing its Q2 2025 earnings results after the market closes on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $49.40 million for the quarter.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.08. The firm had revenue of $52.44 million during the quarter, compared to the consensus estimate of $42.13 million. Adaptive Biotechnologies had a negative net margin of 74.84% and a negative return on equity of 62.79%. The business's revenue was up 25.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.33) earnings per share. On average, analysts expect Adaptive Biotechnologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Adaptive Biotechnologies Price Performance

Shares of NASDAQ ADPT traded up $0.05 during mid-day trading on Wednesday, reaching $10.44. 1,298,568 shares of the company's stock traded hands, compared to its average volume of 1,526,687. The stock has a market cap of $1.59 billion, a P/E ratio of -10.88 and a beta of 1.83. The business has a 50-day simple moving average of $10.59 and a 200 day simple moving average of $8.86. Adaptive Biotechnologies has a 1-year low of $3.85 and a 1-year high of $12.43.

Wall Street Analysts Forecast Growth

Several analysts have commented on ADPT shares. Morgan Stanley lifted their price objective on shares of Adaptive Biotechnologies from $7.00 to $9.00 and gave the stock an "equal weight" rating in a research report on Monday, May 5th. Craig Hallum began coverage on shares of Adaptive Biotechnologies in a research report on Wednesday, June 18th. They issued a "buy" rating and a $15.00 price target on the stock. Piper Sandler reissued an "overweight" rating and issued a $13.00 price target (up previously from $11.00) on shares of Adaptive Biotechnologies in a research report on Tuesday, May 6th. Finally, The Goldman Sachs Group boosted their price target on shares of Adaptive Biotechnologies from $9.00 to $10.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $10.57.

Insider Activity

In other Adaptive Biotechnologies news, insider Harlan S. Robins sold 68,412 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $7.35, for a total transaction of $502,828.20. Following the sale, the insider owned 1,279,524 shares in the company, valued at approximately $9,404,501.40. This trade represents a 5.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.40% of the company's stock.

Institutional Investors Weigh In On Adaptive Biotechnologies

Institutional investors and hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC increased its position in Adaptive Biotechnologies by 45.8% in the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company's stock worth $2,265,000 after purchasing an additional 97,444 shares during the last quarter. Caxton Associates LLP bought a new stake in Adaptive Biotechnologies in the first quarter worth $93,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Adaptive Biotechnologies by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company's stock worth $511,000 after purchasing an additional 2,914 shares during the last quarter. Institutional investors own 99.17% of the company's stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.